Royalty Pharma (RPRX) Reports Q1 Earnings: What Key Metrics Have to Say

For the quarter ended March 2025, Royalty Pharma (RPRX) reported revenue of $839 million, up 17% over the same period last year. EPS came in at$ 1.06, compared to $0.98 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of$ 793.58 million, representing a surprise of +5.72%. The company delivered an EPS surprise of +7.07%, with the consensus EPS estimate being $0.99.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street ...